STPG2 Inhibitors
Chemical inhibitors of STPG2 can achieve functional inhibition through multiple cellular signaling pathways and biochemical mechanisms. Alsterpaullone, a cyclin-dependent kinase inhibitor, disrupts cell cycle regulation, thereby impeding the progression of phases essential for STPG2 activity. Similarly, Bisindolylmaleimide, which inhibits protein kinase C, disrupts signal transduction pathways that STPG2 relies on, resulting in the indirect inhibition of the protein's activity. Y-27632, by selectively inhibiting Rho-associated protein kinase, impairs actin cytoskeleton organization, a process that is crucial for the cellular functions associated with STPG2, thus leading to its inhibition. In the realm of growth factor signaling, Gefitinib impedes the epidermal growth factor receptor's tyrosine kinase, which if integral to STPG2's function, would result in its inhibition due to the disruption of necessary signaling cascades.
Further inhibitory actions are exhibited by LY294002 and Wortmannin, both phosphoinositide 3-kinases inhibitors, that by disrupting PI3K signaling, can lead to a reduction in STPG2 activity by altering its cellular context or substrate availability. PD98059 and U0126, both MEK inhibitors, disrupt the MAPK/ERK pathway, which, if STPG2 is involved in cell growth and differentiation processes mediated by this pathway, would result in its functional inhibition. SB203580 and Sorafenib target the p38 MAP kinase and RAF kinases, respectively, inhibiting signaling pathways that are necessary for STPG2's function. SP600125's inhibition of c-Jun N-terminal kinase similarly impairs signaling events essential for STPG2's activity. Moreover, Rapamycin's inhibition of mTOR, a key regulator of cellular metabolism and growth, can inhibit STPG2 if the protein's function is tied to mTOR-dependent signaling pathways. Each of these chemicals, by targeting specific kinases and signaling pathways, can lead to the functional inhibition of STPG2, provided that the protein's activity is contingent upon these cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs), which are involved in cell cycle regulation. By inhibiting CDKs, alsterpaullone disrupts cell cycle progression, which can lead to the inhibition of STPG2 due to the dependence of the protein's activity on specific cell cycle stages. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide is a protein kinase C (PKC) inhibitor. PKC is implicated in a variety of cellular functions. Inhibition of PKC disrupts signal transduction pathways that STPG2 may rely on for its functional activity, thereby inhibiting STPG2 indirectly. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 selectively inhibits ROCK (Rho-associated protein kinase), which plays a role in actin cytoskeleton organization. Disruption of cytoskeleton dynamics can impair cellular processes that are crucial for STPG2 activity, thus functionally inhibiting the protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. PI3K signaling is vital for many cellular processes, including those that may involve STPG2. Inhibition of PI3K signaling can lead to a reduction in STPG2 activity by altering its cellular context or substrate availability. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK/ERK pathway. This pathway is implicated in cell growth and differentiation. Inhibiting MEK and thus the MAPK/ERK pathway can reduce the functional activity of STPG2 involved in these processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is involved in stress responses. Inhibition of p38 MAP kinase can lead to a decrease in STPG2 activity, as the protein may require p38 MAP kinase-mediated signaling for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of stress-activated protein kinase pathways. Inhibiting JNK can impair signaling events necessary for STPG2's activity, thereby functionally inhibiting the protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002. By inhibiting PI3K, it can disrupt cellular signaling pathways essential for STPG2 function, leading to its inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, similar to PD98059. Inhibiting MEK disrupts the MAPK/ERK pathway, which can lead to a reduction in the functional activity of STPG2, as this protein's function could be tied to this signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR (mechanistic target of rapamycin), a central regulator of cell growth and metabolism. Inhibition of mTOR can impact various signaling pathways and cellular processes, which would be expected to inhibit STPG2's function if it is mTOR-dependent. | ||||||